Drugs / PF-06305591
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05935280 | Jul → Sep 2023 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT01812265 | Jun → Aug 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01776619 | Apr → Nov 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01797796 | Apr → Jul 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01747941 | Nov 2012 → May 2013 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF 06305591 | “150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.” NCT01797796 ↗ |
| Known as | PF-6305591 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297317 ↗ |
| Action | Inhibit | “Specific antagonist of the Nav1.8 sodium channel” NCT05935280 ↗ |
| Modality | Small molecule | — CHEMBL4297317 ↗ |
| Route | Oral | “single oral ascending doses” NCT01747941 ↗ |